Form 4: Amgen EVP David Reese Receives Equity Grant

Amgen Inc. Executive Vice President and Chief Technology Officer David M. Reese was granted restricted stock units and stock options as part of the company's equity incentive plan.

Summary

• David M. Reese, EVP & Chief Technology Officer, received a grant of 2,912 Restricted Stock Units (RSUs) on May 5, 2026.
• A grant of 19,002 non-qualified stock options was issued to the executive on May 5, 2026, with an exercise price of $329.59.
• The executive disposed of 454 shares on May 6, 2026, to satisfy tax withholding obligations related to the vesting of equity awards.
• Following these transactions, the reporting person holds 42,812 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• The equity grants align the interests of the Chief Technology Officer with long-term shareholder value through multi-year vesting schedules.
• The executive maintains a significant direct ownership stake of 42,812 shares.

Negatives

• The transaction involved a tax-related disposition of 454 shares, which is a standard administrative action but reduces the immediate share count.

Risks

• Vesting of the granted RSUs and stock options is subject to continued employment and proration based on active service in 2026.

Future Outlook

The equity awards are subject to a four-year vesting schedule, with 25% vesting annually starting May 5, 2027, contingent upon continued employment.

Industry Context

StockSavvy.ai notes that standard executive equity grants in the biotechnology sector are typical for retention and performance alignment, reflecting standard corporate governance practices at large-cap pharmaceutical firms like Amgen.

Comparison to Industry Standards

• The use of four-year vesting schedules for equity awards is consistent with industry standards for executive compensation at major S&P 500 pharmaceutical companies.
• Tax withholding via share disposition is a standard practice for managing equity compensation at companies like Pfizer, Merck, and Gilead.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard executive retention practices.
• Employees: No direct impact.

Next Steps

• Vesting of the first 25% of the granted RSUs and options on May 5, 2027.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Incentive Plan, Executive Compensation